Meeting
2014 ASCO Annual Meeting
A genome-wide association study (GWAS) of docetaxel-induced neutropenia in CALGB 90401/60404 (Alliance).
Authors
Daniel Louis Hertz
University of Michigan, Ann Arbor, MI
Daniel Louis Hertz , Chen Jiang , Kouros Owzar , Susan Halabi , William Kevin Kelly , Flora Mulkey , Jai Narendra Patel , Michael Anthony Carducci , Michael J. Kelley , Walter Michael Stadler , Mohamed K. Mohamed , Michael J. Morris , Yusuke Nakamura , Hitoshi Zembutsu , Mark J. Ratain , Howard L. McLeod
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Palliative Care and Symptom Management
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 9612)
DOI
10.1200/jco.2014.32.15_suppl.9612
Abstract #
9612
Poster Bd #
262
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
A genome-wide association study (GWAS) of docetaxel-induced peripheral neuropathy in CALGB 90401 (Alliance).
First Author: Daniel Louis Hertz
Poster
2011 ASCO Annual Meeting
Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: X. Huang
Poster
2011 Genitourinary Cancers Symposium
Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Xuan Huang
Poster
2024 ASCO Genitourinary Cancers Symposium
LORIKEET: A phase 2, randomized, open-label study of lorigerlimab plus docetaxel versus docetaxel alone in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Sumit Kumar Subudhi